HBV和HCV相关肝硬化的抗病毒治疗

李瑜元

doi:10.3969/j.issn.1001-5256.2014.07.005

HBV和HCV相关肝硬化的抗病毒治疗

DOI: 10.3969/j.issn.1001-5256.2014.07.005

李瑜元

广州市第一人民医院消化科
广州医科大学

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2609
- HTML全文浏览量: 16
- PDF下载量: 746
- 被引次数: 0
出版历程
- 收稿日期: 2014-02-26
- 出版日期: 2014-07-20

Antiviral therapy for hepatitis B /C virus-related cirrhosis

Li YuYuan

Department of Gastroenterology, Guangzhou First People's Hospital

摘要

摘要: 肝硬化患者抗病毒治疗的必要性和可行性备受关注。综述近年相关指南/共识和循证医学资料,介绍HBV和HCV相关肝硬化抗病毒治疗的适应证、治疗策略、药物选择及治疗收益/风险等方面的进展。资料显示,无论乙型肝炎还是丙型肝炎肝硬化,成功的治疗均可抑制病毒复制,改善病情,延缓疾病进展,延长生存期,减少并发症发生,并为相关肝细胞癌的外科和微创手术创造条件。因核苷和核苷酸类药物安全性好,推荐乙型肝炎肝硬化(包括失代偿期甚至出现并发症)患者尽早使用;而干扰素不良反应多,丙型肝炎肝硬化抗病毒较乙型肝炎困难,须慎重选择适应证。规范抗病毒方案对治疗肝硬化非常重要。
- 肝硬化 /
- 乙型肝炎 /
- 丙型肝炎 /
- 抗病毒药 /
- 综述
Abstract: The necessity and feasibility of antiviral therapy in patients with liver cirrhosis have caught much attention. By summarizing the relevant guidelines /consensus statements and evidence- based medicine data in recent years, the advances in indications, strategies, drug options, and benefit /risk in antiviral therapy for hepatitis B virus (HBV) - and hepatitis C virus (HCV) - related cirrhosis are reviewed. The data reveal that for both HBV- and HCV- related cirrhosis, successful treatment may suppress viral replication, improve patients' conditions, delay disease progression, prolong survival, reduce complications, and create better conditions for surgical and minimally invasive operations for hepatocellular carcinoma. Because of the good safety of nucleos (t) ide analogues (NA) , it is recommended that patients with HBV- related cirrhosis (including those in decompensation stage and with complications) should receive NA as soon as possible. As interferon may cause many adverse reactions, antiviral therapy for HCV- related cirrhosis becomes more difficult than that for HBV- related cirrhosis. Careful selection of indications is necessary. Standardization of the strategies for antiviral therapy is important in the treatment of liver cirrhosis.
- liver cirrhosis /
- hepatitis B /
- hepatitis C /
- antiviral agents /
- review

HTML全文

参考文献(33)

[1]FRETZ R, NEGRO F, BRUGGMANN P, et al.Hepatitis B and C in Switzerland-healthcare provider initiated testing for chronic hepatitis B and C infection[J].Swiss Med Wkly, 2013, 143:w13793.

[2]ROCHE B, SAMUEL D.Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients[J].Clin Liver Dis, 2013, 17 (3) :451-473.

[3]FATTOVICH G, OLIVARI N, PASINO M, et al.Long-tern outcomc of chronic hepatitis B in Caucasian patients:mortality after 25years[J].Gut, 2008, 57 (1) :84-90.

[4]GHANY MG, STRADER DB.THOMAS DI, et al.Diagnosis, management and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.

[5] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[6]Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.

[7]European Association for the study of the Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B[J].J Hepatol, 2009, 50 (2) :227-242.

[8]LOK AS, MCMAHON BJ.Chronic hepatitis B[J].Hepatology, 2007, 45 (2) :507-539.

[9]LIAW YF, LEUNG N, KAO JH, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update[J].Hepatol Int, 2008, 2 (3) :263-283.

[10]Committee of Experts on Antiviral Therapy of Chronic Hepatitis C.Experts consensus on antiviral therapy of chronic hepatitis C[J].Chin J Exp Clin Infect Dis:Electronic Edition, 2009, 8 (3) :343-352. (in Chinese) 慢性丙型肝炎抗病毒治疗专家委员会.慢性丙型肝炎抗病毒治疗专家共识[J].中华实验和临床感染病杂志:电子版, 2009, 8 (3) :343-352.

[11]Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party.Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection[J].J Gastroenterol Hepatol, 2007, 22 (5) :615-633.

[12]CHVEZ-TAPIA NC, RIDRUEJO E, ALVES DE MATTOS A, et al.An update on the management of hepatitis C:guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver[J].Ann Hepatol, 2013, 12 (Suppl 2) :s3-s35.

[13]ILOEJE UH, YANG HI, SU J, et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J].Gastroenterology, 2006, 130 (3) :678-686.

[14] CHEN CJ, YANG HI, SU J, et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J].JAMA, 2006, 295 (1) :65-73.

[15]ROCHE B, SAMUEL D.Antiviral therapy in HCV-infected cirrhoties awaiting liver transplantation:a costly strategy for mixed virological results[J].J Hepatol, 2009, 50 (4) :652-654.

[16]KUMADA T, TOYODA H, TADA T, et al.Effect of nucleos (t) ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:a propensity score analysis[J].J Hepatol, 2013, 58 (3) :427-433.

[17]ABU-AMARA M, FELD JJ.Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?[J].Semin Liver Dis, 2013, 33 (2) :157-166.

[18]YU ML, HUANG CF, DAI CY, et al.Long-term effects of interferon-based therapy for chronic hepatitis C[J].Oncology, 2007, 72 (Suppl 1) :16-23.

[19]REALDI G, FATTOVICH G, HADZIYANNIS S, et al.Survival and prognostic factors in 366 patients with compensated cirrhosis type B:a multicenter study.The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP) [J].J Hepatol, 1994, 21 (4) :656-666.

[20]BRUNO S, SHIFFMAN ML, ROBERTS SK, et al.Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis[J].Hepatology, 2010, 51 (2) :388-397.

[21]LIAW YF, SUNG JJ, CHOW WC, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) :1521-1531.

[22]SINGAL AK, FONTANA RJ.Meta-analysis:oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis[J].Aliment Pharmacol Ther, 2012, 35 (6) :674-689.

[23]SOMASUNDARAM A, VENKATARAMAN J.Antiviral treatment for cirrhosis due to hepatitis C:a review[J].Singapore Med J, 2012, 53 (4) :231-235.

[24]BOTA S, SPOREA I, SIRLI R, et al.Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients:a systematic review[J].World J Hepatol, 2013, 5 (3) :120-126.

[25]BRUNO S, CROSIGNANI A, FACCIOTTO C, et al.Sustained virologic response prevents the development of esophageal varices incompensated, Child-Pugh class A hepatitis C virus-induced cirrhosis.A 12-year prospective follow-up study[J].Hepatology, 2010, 51 (6) :2069-2076.

[26]TAN ZM, SUN BC.Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence[J].World J Gastroenterol, 2013, 19 (47) :8895-8901.

[27] Liver Cancer Group, Chinese Society of Hepatology.Expert advices on antiviral therapy for HBV-and HCV-related hepatocellular carcinoma[J].Chin J Dig, 2013, 33 (2) :73-79. (in Chinese) 中华医学会肝病学分会肝癌学组.乙型肝炎、丙型肝炎病毒相关性肝细胞癌抗病毒治疗专家建议[J].中华消化杂志, 2013, 33 (2) :73-79.

[28]Chinese Expert Consensus Statement Chinese Society of Liver Cancer (CSLC) , Chinese Society of Clinical Oncology (CSCO) , Liver Cancer Group, Chinese Society of Hepatology.Consensus on standardized diagnosis and treatment of primary liver cancer[J].J Clin Hepatol, 2009, 25 (2) :83-92. (in Chinese) 中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].临床肝胆病杂志, 2009, 25 (2) :83-92.

[29]LV GC, YAO JM, YANG YD, et al.Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis[J].World J Gastroenterol, 2013, 19 (22) :3481-3486.

[30]YANG J, ZHU X, WANG H.Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis[J].J Cent South Univ:Med Sci, 2012, 37 (12) :1269-1273. (in Chinese) 杨静, 朱萱, 王河.拉米夫定初始联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化的疗效观察[J].中南大学学报:医学版, 2012, 37 (12) :1269-1273.

[31]LIAN JS, ZENG LY, CHEN JY, et al.De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis[J].World J Gastroenterol, 2013, 19 (37) :6278-6283.

[32]PENG H, LIU J, YANG M, et al.Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis:A meta-analysis[J].J Clin Pharmacol, 2014, 54 (2) :189-200.

[33]LEMOINE M, NAYAGAM S, THURSZ M.Viral hepatitis in resource-limited countries and access to antiviral therapies:current and future challenges[J].Future Virol, 2013, 8 (4) :371-380.

施引文献

资源附件(0)

访问统计